Guojie Cheng

Guojie Cheng

Auto-generated profile, based on publicly available information

Guojie Cheng

Department of Cardiology, Beijing Daxing District People’s Hospital, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Disease Markers
Verified
Journal Article
Open access
PDF file
QJQingwei Ji
Qingwei Ji
GCGuojie Cheng
Guojie Cheng
NMNing Ma
Ning Ma
YHYing Huang
Ying Huang
YLYingzhong Lin
Yingzhong Lin
SNShaoping Nie
Shaoping Nie
Background. Evidence from experimental studies showed that Th1, Th2, and Th17 play a pivotal role in hypertension and target organ damage. However, whether changes in the circulating Th1, Th2, and Th17 levels are associated with nondipper hypertension and carotid atherosclerotic plaque in hypertension has yet to be investigated. Methods. Th1, Th2, and Th17 levels were detected using a flow cytometric analysis, and their related cytokines were measured by enzyme-linked immunosorbent assay in 45 hypertensive patients and 15 normotensive subjects. Results. The frequencies of Th1 and Th17 in hypertensive patients, especially in nondipper patients and patients with carotid atherosclerotic plaque, were markedly higher than those in the control group; this was accompanied by higher IFN-γ and IL-17 levels. In contrast, the Th2 frequencies and IL-4 levels in hypertensive patients, especially in nondipper patients and patients with carotid atherosclerotic plaque, were significantly lower than those in the control group. Conclusions. The changes in Th1, Th2, and Th17 activity are associated with the onset of the nondipper type and carotid atherosclerotic plaque in hypertensive patients.

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
XZXiliang Zhao
Xiliang Zhao
GCGuojie Cheng
Guojie Cheng
LSLiling Sun
Liling Sun
YLYajuan Liu
Yajuan Liu
XDXin Du
Xin Du
YZYong Zeng
Yong Zeng
Purpose: Coronary artery disease represents a major clinical burden, and angina pectoris is the most frequent manifestation of coronary artery disease. Nicorandil is commonly used for the management of angina pectoris; however, its effects on health status outcomes are unclear. Patients and Methods: This multicenter, prospective, cohort study (GREAT) enrolled 1556 adult coronary artery disease patients with angina pectoris from nine hospitals in China. Patients were classified into nicorandil and control groups. The primary outcome was the change in the Seattle Angina Questionnaire summary score (SAQ-SS) from baseline to 12 months. Secondary outcomes included changes in SAQ-SS at 3, 6, and 9 months. Propensity score matching (PSM) was used to reduce bias and control for confounding factors. Results: We analyzed 1528 patients with baseline and 12-month health status data. After PSM, 450 matched pairs of patients were identified. A difference of ≥ 5 points for SAQ-SS is considered clinically significant. Patients in the nicorandil group reported greater mean improvement in SAQ-SS (17.6 ± 14.0, difference: 2.50, 95% CI: 0.74– 4.27; P=0.003) at 12 months compared with the control group (15.1 ± 13.0; P=0.003). Similar trends were noted in SAQ-SS at 3, 6, and 9 months. Additionally, nicorandil users exhibited significantly greater improvements in the SAQ physical limitation (11.7 ± 16.9 vs 8.4 ± 16.9; difference: 3.27, 95% CI, 1.05– 5.48; P =0.001) and SAQ-QoL domain (18.9 ± 21.4 vs 16.3 ± 20.4; difference: 2.62, 95% CI, − 0.12 to 5.35; P=0.042) at 12 months. Most patients in the entire cohort (78.4%) reported a clinical improvement in SAQ-SS. The nicorandil group had a higher proportion of patients with at least large improvements (≥ 20 points) in SAQ-SS (42.5% vs 32.9%; difference: 9.7%, 95% CI: 3.3– 16.0; P= 0.004). Conclusion: Among patients with angina pectoris, anti-angina treatment improved the majority of patients’ health status. Nicorandil-based regimens were associated with a greater health status outcome improvement compared to those not using nicorandil in coronary artery disease patients with angina pectoris. A substantial proportion of patients using nicorandil exhibited noteworthy improvements in health status outcomes at one year. Registration: ClinicalTrials.gov, NCT05050773.